Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1995 1
1998 1
2002 1
2003 1
2004 2
2005 2
2006 2
2007 3
2008 3
2009 4
2010 4
2011 3
2012 6
2013 3
2014 6
2015 4
2016 4
2017 2
2018 3
2019 2
2020 2
2021 1
2023 3

Text availability

Article attribute

Article type

Publication date

Search Results

56 results

Results by year

Filters applied: . Clear all
Page 1
Discovery of Futibatinib: The First Covalent FGFR Kinase Inhibitor in Clinical Use.
Ito S, Otsuki S, Ohsawa H, Hirano A, Kazuno H, Yamashita S, Egami K, Shibata Y, Yamamiya I, Yamashita F, Kodama Y, Funabashi K, Kazuno H, Komori T, Suzuki S, Sootome H, Hirai H, Sagara T. Ito S, et al. Among authors: shibata y. ACS Med Chem Lett. 2023 Mar 10;14(4):396-404. doi: 10.1021/acsmedchemlett.3c00006. eCollection 2023 Apr 13. ACS Med Chem Lett. 2023. PMID: 37077386
A dosimetric and centeredness comparison of the conventional and novel endobronchial applicators: A preliminary study.
Iijima K, Murakami N, Okamoto H, Nakamura S, Nishioka S, Chiba T, Kuwahara J, Nakayama H, Takemori M, Aikawa A, Yoshihiro S, Kashihara T, Takahashi K, Inaba K, Okuma K, Igaki H, Nakayama Y, Itami J. Iijima K, et al. Among authors: yoshihiro s. Brachytherapy. 2021 Mar-Apr;20(2):467-477. doi: 10.1016/j.brachy.2020.11.005. Epub 2021 Jan 19. Brachytherapy. 2021. PMID: 33353847
Discovery of a Novel ATP-Competitive MEK Inhibitor DS03090629 that Overcomes Resistance Conferred by BRAF Overexpression in BRAF-Mutated Melanoma.
Takano K, Munehira Y, Hatanaka M, Murakami R, Shibata Y, Shida T, Takeuchi K, Takechi S, Tabata T, Shimada T, Kishikawa S, Matsui Y, Ubukata O, Seki T, Kaneta Y. Takano K, et al. Among authors: shibata y. Mol Cancer Ther. 2023 Mar 2;22(3):317-332. doi: 10.1158/1535-7163.MCT-22-0306. Mol Cancer Ther. 2023. PMID: 36622773
Discovery of Novel Pyrido-pyridazinone Derivatives as FER Tyrosine Kinase Inhibitors with Antitumor Activity.
Taniguchi T, Inagaki H, Baba D, Yasumatsu I, Toyota A, Kaneta Y, Kiga M, Iimura S, Odagiri T, Shibata Y, Ueda K, Seo M, Shimizu H, Imaoka T, Nakayama K. Taniguchi T, et al. Among authors: shibata y. ACS Med Chem Lett. 2019 Mar 15;10(5):737-742. doi: 10.1021/acsmedchemlett.8b00631. eCollection 2019 May 9. ACS Med Chem Lett. 2019. PMID: 31097992 Free PMC article.
Discovery of DF-461, a Potent Squalene Synthase Inhibitor.
Ichikawa M, Ohtsuka M, Ohki H, Ota M, Haginoya N, Itoh M, Shibata Y, Ishigai Y, Terayama K, Kanda A, Sugita K. Ichikawa M, et al. Among authors: shibata y. ACS Med Chem Lett. 2013 Sep 4;4(10):932-6. doi: 10.1021/ml400151c. eCollection 2013 Oct 10. ACS Med Chem Lett. 2013. PMID: 24900587 Free PMC article.
B cell activation regulates exosomal HLA production.
Arita S, Baba E, Shibata Y, Niiro H, Shimoda S, Isobe T, Kusaba H, Nakano S, Harada M. Arita S, et al. Among authors: shibata y. Eur J Immunol. 2008 May;38(5):1423-34. doi: 10.1002/eji.200737694. Eur J Immunol. 2008. PMID: 18425730 Free article.
The risk factors for oxaliplatin-induced peripheral sensory neuropathy and thrombocytopenia in advanced gastric cancer.
Yamaguchi K, Kusaba H, Makiyama A, Mitsugi K, Uchino K, Tamura S, Shibata Y, Esaki T, Ito M, Takayoshi K, Tsuchihashi K, Arita S, Ariyama H, Akashi K, Baba E. Yamaguchi K, et al. Among authors: shibata y. Cancer Chemother Pharmacol. 2018 Oct;82(4):625-633. doi: 10.1007/s00280-018-3652-2. Epub 2018 Jul 24. Cancer Chemother Pharmacol. 2018. PMID: 30043209
56 results